Why an Efficacious Drug Therapy for Narcolepsy Is Underused
Low prescribing rates persist even as evidence supports benefit, pointing to missed conversations, unclear expectations, and fragile early treatment periods.
Low prescribing rates persist even as evidence supports benefit, pointing to missed conversations, unclear expectations, and fragile early treatment periods.
Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.
The FDA has approved Avadel Pharmaceuticals' LUMRYZ for pediatric patients aged 7 and older with narcolepsy, offering a once-nightly treatment for cataplexy and excessive daytime sleepiness.
A post-hoc analysis confirmed the efficacy of Lumryz in study participants who were and were not using a stable dose of an alerting agent.
Read MoreA new report illuminates the real-world experiences and treatment needs of individuals with idiopathic hypersomnia.
Read MoreSurvey data demonstrate that 94% of people with narcolepsy prefer the once-nightly regimen of Lumryz over twice-nightly oxybate regimens.
Read MoreNearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.
Read MoreAvadel reports advancements for Lumryz, including a phase 3 trial for idiopathic hypersomnia and an upcoming FDA decision on pediatric narcolepsy.
Read MoreThe study will evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a once-at-bedtime treatment for idiopathic hypersomnia.
Read MoreAvadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.
Read MorePatient usage of Lumryz in increased 70% in Q1, while Avadel plans to expand into pediatric treatment and launch a phase 3 trial in idiopathic hypersomnia.
Read MoreA jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.
Read MoreAvadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
Read MoreSleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read MoreAvadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.
Read MoreAvadel Pharmaceuticals announced new and encore data abstracts emphasizing the clinical benefit of Lumryz and patient preference for a once-at-bedtime narcolepsy treatment option.
Read MoreAvadel aims to expand the potential of Lumryz with a supplemental New Drug Application filing planned in the second half of 2023 for Lumryz in the pediatric narcolepsy population.
Read MoreThis will be Avadel’s third year as lead sponsor of the YIRF program, which takes place through June, with virtual events and in-person events.
Read More